Boehringer Ingelheim and Re-Vana Therapeutics, a US- and UK-based developer of ocular drug delivery technologies, have announced a strategic collaboration and licensing agreement aimed at developing extended-release therapies for eye diseases. The deal could be worth more than $1 billion for the initial three treatment targets and includes milestone and royalty payments.
This partnership seeks to address a major challenge in ophthalmic care — the frequent intravitreal injections required for many eye disease treatments. Re-Vana’s technology enables the slow release of therapeutics over six to 12 months, significantly reducing injection frequency and potentially improving patient adherence and outcomes.
Boehringer Ingelheim, which already has four assets in Phase II development in its growing eye health pipeline, will apply Re-Vana’s drug delivery platform across multiple therapeutic programs. The companies plan to initiate up to three new projects per year, with Boehringer Ingelheim leading clinical development, regulatory approval, and commercialization efforts.
Nedim Pipic, Global Head of Mental Health, Eye Health, and Emerging Areas at Boehringer Ingelheim, emphasized the significance of the partnership: “This collaboration with Re-Vana is a bold step in tackling the limitations of current eye disease treatments. Together, we aim to protect vision while reducing the burden on patients.”
Michael O’Rourke, CEO of Re-Vana, called the deal “transformational,” noting that “by combining our extended-release platform with Boehringer Ingelheim’s R&D and pipeline, we strive to bring forward a new generation of long-acting therapies that improve both clinical outcomes and quality of life for patients.”
The agreement grants target exclusivity to Boehringer Ingelheim and includes upfront payments as well as development, regulatory, and commercial milestones, plus royalties on net sales.
This collaboration marks a major step toward creating more patient-friendly and effective long-term therapies for chronic eye conditions, and reflects Boehringer Ingelheim’s growing commitment to innovation in ophthalmology.